Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
37.42
59.36
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one RARE stock under the Base Case scenario is 66.1 USD. Compared to the current market price of 47.24 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ultragenyx Pharmaceutical Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for RARE cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Ultragenyx Pharmaceutical Inc
Balance Sheet Decomposition
Ultragenyx Pharmaceutical Inc
Current Assets | 799.6m |
Cash & Short-Term Investments | 621.6m |
Receivables | 93.3m |
Other Current Assets | 84.7m |
Non-Current Assets | 738.8m |
Long-Term Investments | 203.1m |
PP&E | 272.4m |
Intangibles | 209.3m |
Other Non-Current Assets | 53.9m |
Current Liabilities | 285m |
Accounts Payable | 36m |
Accrued Liabilities | 195.5m |
Other Current Liabilities | 53.6m |
Non-Current Liabilities | 906.5m |
Other Non-Current Liabilities | 906.5m |
Earnings Waterfall
Ultragenyx Pharmaceutical Inc
Revenue
|
522.7m
USD
|
Cost of Revenue
|
-71.9m
USD
|
Gross Profit
|
450.9m
USD
|
Operating Expenses
|
-986.6m
USD
|
Operating Income
|
-535.7m
USD
|
Other Expenses
|
-23.2m
USD
|
Net Income
|
-559m
USD
|
Free Cash Flow Analysis
Ultragenyx Pharmaceutical Inc
USD | |
Free Cash Flow | USD |
In Q3 2024, Ultragenyx achieved $139 million in total revenue, marking a significant 42% increase from the previous year. The robust performance was led by Crysvita, which generated $98 million. Operating expenses totaled $271 million, resulting in a net loss of $134 million. The company reaffirmed its 2024 total revenue guidance of $530-$550 million, expecting Crysvita sales to reach $375-$400 million. Notably, Ultragenyx is progressing on three late-stage drug applications, aiming for potential approvals soon, which could enhance revenue streams and advance towards profitability by late 2026.
What is Earnings Call?
RARE Profitability Score
Profitability Due Diligence
Ultragenyx Pharmaceutical Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Ultragenyx Pharmaceutical Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
RARE Solvency Score
Solvency Due Diligence
Ultragenyx Pharmaceutical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Ultragenyx Pharmaceutical Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for RARE is 94.42 USD with a low forecast of 48.48 USD and a high forecast of 147 USD.
Dividends
Current shareholder yield for RARE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
RARE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The company is headquartered in Novato, California and currently employs 1,119 full-time employees. The company went IPO on 2014-01-31. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.
Contact
IPO
Employees
Officers
The intrinsic value of one RARE stock under the Base Case scenario is 66.1 USD.
Compared to the current market price of 47.24 USD, Ultragenyx Pharmaceutical Inc is Undervalued by 29%.